This inventor holds 3 USPTO granted patents and 20 published patent applications and 1 EPO patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2021-2025.
Location History:
- Jammu, IN (2021)
- Chandigarh, IN (2024)
Company Filing History:
Years Active: 2021-2025
Title: Deepak Kumar Sharma: Innovator in Protein Aggregation Inhibition
Introduction
Deepak Kumar Sharma is a prominent inventor based in Chandigarh, India. He has made significant contributions to the field of biotechnology, particularly in the development of peptide-based inhibitors for protein aggregation. With a total of 3 patents to his name, Sharma's work is paving the way for advancements in the treatment of amyloid-related disorders.
Latest Patents
Sharma's latest patents include innovative solutions such as a recombinant vector for high-expression of proteins in yeasts. Additionally, he has developed potent peptide inhibitors of protein aggregation. One of his notable disclosures provides a novel peptide that serves as a potent inhibitor of protein aggregation, featuring a specific formula that includes various amino acids and functional groups. This research is crucial for addressing amyloid-related disorders, which pose significant health challenges.
Career Highlights
Deepak Kumar Sharma is affiliated with the Council of Scientific and Industrial Research, where he continues to push the boundaries of scientific research. His work not only contributes to academic knowledge but also has practical implications for medical treatments.
Collaborations
Sharma collaborates with esteemed colleagues such as Gautam Ankur and Gajendra Pal Singh Raghava. These partnerships enhance the scope and impact of his research, fostering a collaborative environment for innovation.
Conclusion
Deepak Kumar Sharma's contributions to the field of biotechnology, particularly in the area of protein aggregation inhibition, highlight his role as a leading inventor. His innovative patents and collaborations are set to make a lasting impact on the treatment of amyloid-related disorders.
